SCHEMBL3460160

SCHEMBL3460160

O=C1CCc2cc(-c3cccs3)ccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 4/20 0.53
SRD5A1 P18405 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
SLC6A11 P48066 1/20 0.47
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KCNH2 Q12809 1/20 0.45
PGR P06401 2/20 0.43
GRM5 P41594 1/20 0.43
ADORA1 P30542 1/20 0.42
ERN1 O75460 1/20 0.42
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
DRD3 P35462 2/20 0.41
PDK2 Q15119 1/20 0.40
PRF1 P14222 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7505848 0.91 HSD17B1 (0.55) HSD17B1SRD5A1CYP1A2CYP11B1CYP11B2
SCHEMBL31358816 0.79 ADORA1 (0.55) SRD5A1CYP11B1CYP11B2SLC6A11KCNH2
SCHEMBL2238249 0.79 ADORA1 (0.55) SRD5A1CYP11B1CYP11B2SLC6A11KCNH2
SCHEMBL15570510 0.79 PARP11 (0.62) SLC6A11GRM5PRF1
SCHEMBL28655414 0.78 HSD17B1 (0.78) HSD17B1CYP1A2CYP11B1CYP11B2CASP1
SCHEMBL4243227 0.78 SLC6A11 (0.48) HSD17B1SRD5A1SLC6A11KCNH2PGR
SCHEMBL15570926 0.77 DRD2 (0.52) SRD5A1SLC6A11GRM5DRD2DRD4
SCHEMBL27690419 0.76 MAOB (0.51) SLC6A11KCNH2PGRGRM5
SCHEMBL15570741 0.75 CLK4 (0.54) SLC6A11KCNH2PGRGRM5PRF1
SCHEMBL1745161 0.74 HSD17B1 (0.71) HSD17B1SRD5A1CYP1A2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104910053-B Asymmetric two oxime ester compound and its manufacture method and application 北京英力科技发展有限公司 2017-09-12 CN disclosed
CN-103998422-B Cyclopentanedione oxime ester and application thereof 北京英力科技发展有限公司 2016-11-30 CN disclosed
CN-104910053-A Asymmetric dioxime ester compound, making method and application thereof INSIGHT HIGH TECHNOLOGY BEIJING CO LTD 2015-09-16 CN disclosed
CN-103998422-A Cyclopentadiketoxime ester and applications thereof BEIJING INSIGHT HIGH TECHNOLOGY CO LTD 2014-08-20 CN disclosed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 EP disclosed
CN-101119965-B Tetralin and indane derivatives and uses thereof HOFFMANN LA ROCHE 2012-09-26 CN disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 US disclosed
EP-1501514-A4 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-08-26 EP disclosed
CN-101124210-A Tetrahydronaphthalene and indane derivatives and their use ROCHE PALO ALTO LLC (CH) 2008-02-13 CN disclosed
CN-101119965-A Tetralin and indane derivatives and uses thereof ROCHE PALO ALTO LLC (CH) 2008-02-06 CN disclosed
CN-101111472-A 1,2,3, 4-tetrahydronaphthalene and indane derivatives and their use as 5-HT antagonists HOFFMANN LA ROCHE (CH) 2008-01-23 CN disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 EP disclosed
EP-1119557-B1 INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS AVENTIS PHARMA GMBH (DE) 2003-12-03 EP disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 WO disclosed
EP-1119557-A1 INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-08-01 EP disclosed
US-6090833-A EATING DISORDERS; ANTIDIABETIC AGENT AVENTIS PHARMA DEUTSCHAND GMBH (DE) 2000-07-18 US disclosed
WO-2000018749-A1 INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 HSD17B1 2835/4885SRD5A1 3529/4885CYP1A2 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.